Efficacy of substituting innovator propafenone for its generic formulation in patients with atrial fibrillation.
The clinical outcomes of 114 patients with atrial fibrillation who had been treated with the innovator propafenone, and in whom the drug was then replaced with generic propafenone because of cost containment, were compared. The generic formulation was found to be at least as safe and effective as the innovator drug, with regard to atrial fibrillation recurrence, emergency room and hospital admissions, and necessity for concomitant therapy.
Amit
Guy
G
Faculty of Health Sciences, Soroka University Medical Center, Ben-Gurion University, Beer Sheva, Israel.
Rosen
Amit
A
Wagshal
Avraham B
AB
Bonneh
Dan Y
DY
Liss
Tzvika
T
Grosbard
Aviva
A
Ilia
Reuven
R
Katz
Amos
A
D000368:Aged; D000369:Aged, 80 and over; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy*; D015331:Cohort Studies; D016568:Drugs, Generic / Q000627:therapeutic use*; D004636:Emergency Service, Hospital / Q000706:statistics & numerical data; D005260:Female; D006801:Humans; D008297:Male; D010343:Patient Admission / Q000706:statistics & numerical data; D011405:Propafenone / Q000627:therapeutic use*; D012008:Recurrence; D012189:Retrospective Studies; D013810:Therapeutic Equivalency; D016896:Treatment Outcome
D000889:Anti-Arrhythmia Agents; D016568:Drugs, Generic; D011405:Propafenone